Healthcare provider profile · identity verified

Joshua Cullison, MD

Family Practice · BLOOMFIELD, IN · NPI 1245593300

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	383	121
Lisinopril	Lisinopril	264	74
Amlodipine Besylate	Amlodipine Besylate	236	73
Gabapentin	Gabapentin	187	43
Omeprazole	Omeprazole	180	56
Levothyroxine Sodium	Levothyroxine Sodium	155	49
Metoprolol Succinate	Metoprolol Succinate	131	37
Losartan Potassium	Losartan Potassium	127	47
Pravastatin Sodium	Pravastatin Sodium	120	37
Albuterol Sulfate Hfa	Albuterol Sulfate	118	33
Furosemide	Furosemide	118	34
Metformin Hcl	Metformin Hcl	117	42
Tamsulosin Hcl	Tamsulosin Hcl	99	28
Potassium Chloride	Potassium Chloride	93	27
Ozempic	Semaglutide	91	26
Alprazolam	Alprazolam	78	19
Hydrochlorothiazide	Hydrochlorothiazide	76	24
Allopurinol	Allopurinol	73	23
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	70	23
Pantoprazole Sodium	Pantoprazole Sodium	69	22
Carvedilol	Carvedilol	64	18
Fluoxetine Hcl	Fluoxetine Hcl	64	19
Jardiance	Empagliflozin	62	20
Alendronate Sodium	Alendronate Sodium	60	21
Montelukast Sodium	Montelukast Sodium	59	17
Rosuvastatin Calcium	Rosuvastatin Calcium	59	20
Glipizide	Glipizide	57	19
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	57	12
Metoprolol Tartrate	Metoprolol Tartrate	54	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	16
Meloxicam	Meloxicam	47	18
Pregabalin	Pregabalin	46	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	44	16
Spironolactone	Spironolactone	44	14
Farxiga	Dapagliflozin Propanediol	41	14
Sertraline Hcl	Sertraline Hcl	40	18
Amitriptyline Hcl	Amitriptyline Hcl	38	suppressed
Breo Ellipta	Fluticasone/Vilanterol	37	suppressed
Clopidogrel	Clopidogrel Bisulfate	37	suppressed
Diazepam	Diazepam	35	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	35	suppressed
Prednisone	Prednisone	34	22
Tizanidine Hcl	Tizanidine Hcl	34	11
Duloxetine Hcl	Duloxetine Hcl	33	11
Enalapril Maleate	Enalapril Maleate	33	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	33	11
Mounjaro	Tirzepatide	33	suppressed
Trazodone Hcl	Trazodone Hcl	33	11
Escitalopram Oxalate	Escitalopram Oxalate	32	13
Simvastatin	Simvastatin	32	12
Clonidine Hcl	Clonidine Hcl	31	suppressed
Tramadol Hcl	Tramadol Hcl	29	suppressed
Clonazepam	Clonazepam	28	suppressed
Eliquis	Apixaban	28	suppressed
Famotidine	Famotidine	28	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	28	suppressed
Buspirone Hcl	Buspirone Hcl	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Atenolol	Atenolol	26	suppressed
Ezetimibe	Ezetimibe	26	suppressed
Ibuprofen	Ibuprofen	26	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Ondansetron Odt	Ondansetron	25	suppressed
Fluticasone Propionate	Fluticasone Propionate	24	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	11
Donepezil Hcl	Donepezil Hcl	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Klor-Con M20	Potassium Chloride	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	18
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	18	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	18	suppressed
Lorazepam	Lorazepam	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	11
Sucralfate	Sucralfate	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Baclofen	Baclofen	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Primidone	Primidone	13	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Naproxen	Naproxen	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Testosterone Cypionate	Testosterone Cypionate	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Valsartan	Valsartan	12	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Finasteride	Finasteride	11	suppressed
Humalog Kwikpen U-200	Insulin Lispro	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error